Fractyl’s Rejuva platform demonstrates potent and durable effects of a single dose of a human GLP-1 pancreatic gene therapy transgene vs semaglutide for diabetes and obesity
Fractyl Health has revealed promising new preclinical findings for the first clinical candidate in its Rejuva pancreatic gene therapy...
